Akebia Therapeutics is a pharmaceutical company, which focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The Company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme.
Type
Public
HQ
Cambridge, US
Founded
2007
Size (employees)
90 (est)
Website
akebia.com
Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, US
Report incorrect company information

Akebia Therapeutics Office Locations

Akebia Therapeutics has an office in Cambridge
Cambridge, US (HQ)
1100 245 First St
Show all (1)
Report incorrect company information

Akebia Therapeutics Financials and Metrics

Akebia Therapeutics Financials

USD

Net income (Q1, 2018)

(23.4 m)

EBIT (Q1, 2018)

(24.5 m)

Market capitalization (22-Jun-2018)

611.5 m

Closing share price (22-Jun-2018)

10.8

Cash (31-Mar-2018)

158.2 m
Akebia Therapeutics's current market capitalization is $611.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

12.5 m18.5 m22.2 m27 m

R&D expense

25.4 m43 m115.8 m230.9 m

Operating expense total

37.9 m61.5 m138 m257.9 m

EBIT

(37.9 m)(61.5 m)(136.5 m)(79.9 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

3.4 m3.7 m3.9 m5.8 m5.3 m4.9 m5.8 m6.9 m9 m

R&D expense

7.5 m7.2 m15.8 m20.2 m30.9 m31.2 m60 m43.8 m61.4 m

Operating expense total

10.9 m10.9 m19.7 m26 m36.2 m36.2 m65.8 m50.7 m70.4 m

EBIT

(10.9 m)(10.9 m)(19.7 m)(26 m)(36.2 m)(36.2 m)(45 m)(22.1 m)(24.5 m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

32.8 m49.8 m187.3 m70.2 m

Accounts Receivable

48 k933 k34.2 m

Inventories

1.5 m2.6 m2.2 m

Current Assets

110.5 m141 m296.3 m358.4 m
Quarterly
USDQ1, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

126.3 m27.9 m76.2 m66.7 m43.4 m46.2 m65.8 m87.3 m125.4 m158.2 m

Accounts Receivable

119.4 k74 k48 k14 k35.9 m

Current Assets

133.7 m102.7 m155 m158.8 m219.5 m192.5 m165.1 m255.1 m332.4 m437 m

PP&E

404 k398 k479 k629 k1.8 m2.7 m2.9 m2.9 m3.7 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(37 m)(60.7 m)(135.7 m)(76.9 m)

Depreciation and Amortization

49.4 k96 k296 k617 k

Inventories

(773 k)(1 m)428 k

Accounts Payable

4.1 m231 k(274 k)5 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(9.7 m)(10.7 m)(10.7 m)(19.5 m)(25.8 m)(35.8 m)(36.3 m)(44.5 m)(23.4 m)

Depreciation and Amortization

8.1 k199 k

Accounts Payable

1.9 m1.5 m3 m4.3 m2.4 m5.3 m2.4 m5.1 m8.5 m15.1 m10.9 m

Cash From Operating Activities

(6 m)(20.3 m)
USDY, 2018

Financial Leverage

2.2 x
Show all financial metrics
Report incorrect company information

Akebia Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information